Prognostic significance of CD24 protein expression in patients treated with adjuvant radiotherapy after radical hysterectomy for cervical squamous cell carcinoma.
OBJECTIVE
The CD24 marker is expressed in various carcinomas and is associated with shorter survival rates. We evaluated the prognostic significance of CD24 protein overexpression in patients treated with post-operative radiotherapy (RT) after surgery, and its prognostic significance and specific role stratified by adjuvant treatment modalities.


METHODS
We determined the CD24 expression status of 140 patients with cervical squamous cell carcinoma treated with RT alone or with chemoradiotherapy (CRT) after radical hysterectomy procedures.


RESULTS
CD24 expression was detected in 59 patients (42%) and was significantly associated with locoregional failure-free survival (LRFFS) (p=0.0218), distant metastasis-free survival (DMFS) (p=0.0001), and overall survival (OS) (p=0.0053). In the multivariate analysis, CD24 positivity was also significantly associated with DMFS (p=0.025) and OS (p=0.045). CD24 expression stratified by post-operative treatments (CRT or RT alone) was associated with DMFS (p=0.0001) but not with LRFFS (p=0.4423) in the CRT group. However, CD24 expression was associated with LRFFS (p=0.0198) but not with DMFS (p=0.5269) in the RT alone group.


CONCLUSIONS
CD24 expression is an independent prognostic marker in patients with cervical squamous cell carcinoma, even adjuvant treatment after surgery. And this study reveals different prognostic role of CD24 expression in two subgroups treated differently after surgery. Therefore, new therapeutic strategies targeting CD24 expression stratified by subgroups might have important clinical implications.
Sung
Chang Ohk
CO
Department of Pathology, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Park
Won
W
Choi
Yoon-La
YL
Ahn
Geunghwan
G
Song
Sang Yong
SY
Huh
Seung Jae
SJ
Bae
Duk Soo
DS
Kim
Byoung Gie
BG
Lee
Je Ho
JH
D000328:Adult; D000368:Aged; D051927:CD24 Antigen / Q000032:analysis*; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007044:Hysterectomy; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis; D008875:Middle Aged; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*
D051927:CD24 Antigen; C497889:CD24 protein, human